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Abstract
Background: The recently described Designed Ankyrin Repeat Protein (DARPin) technology can produce highly selective
ligands to a variety of biological targets at a low production cost.
Methodology/Principal Findings: To investigate the in vivo use of DARPins for future application to novel anti-HIV
strategies, we identified potent CD4-specific DARPins that recognize rhesus CD4 and followed the fate of intravenously
injected CD4-specific DARPin 57.2 in rhesus macaques. The human CD4-specific DARPin 57.2 bound macaque CD4
+ cells
and exhibited potent inhibitory activity against SIV infection in vitro. DARPin 57.2 or the control E3_5 DARPin was injected
into rhesus macaques and the fate of cell-free and cell-bound CD4-specific DARPin was evaluated. DARPin-bound CD4
+ cells
were detected in the peripheral blood as early as 30 minutes after the injection, decreasing within 6 hours and being almost
undetectable within 24 hours. The amount of DARPin bound was dependent on the amount of DARPin injected. CD4-
specific DARPin was also detected on CD4
+ cells in the lymph nodes within 30 minutes, which persisted with similar kinetics
to blood. More extensive analysis using blood revealed that DARPin 57.2 bound to all CD4
+ cell types (T cells, monocytes,
dendritic cells) in vivo and in vitro with the amount of binding directly proportional to the amount of CD4 on the cell
surface. Cell-free DARPins were also detected in the plasma, but were rapidly cleared from circulation.
Conclusions/Significance: We demonstrated that the CD4-specific DARPin can rapidly and selectively bind its target cells in
vivo, warranting further studies on possible clinical use of the DARPin technology.
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Introduction
Antibodies, generated in vivo or by selection from libraries in
vitro, are widely used for the treatment of a variety of conditions,
such as malignancies, transplant rejection and autoimmune
disorders [1,2]. However, antibodies have relatively high produc-
tion costs and depend on intact disulfide bonds for stability. In
contrast, recently described Designed Ankyrin Repeat Proteins
(DARPins) are immunologically silent, have superior stability and
can be cheaply produced in prokaryotic systems, while maintain-
ing high selectivity and affinity for the target that they are selected
against [3,4]. DARPin technology is already effectively used in
biomedical research and potentially could be used in treatment
and prevention of disease, including HIV infection.
Ankyrin repeat proteins are a family of proteins that are found
across multiple species and mediate protein-protein interactions in
various cell compartments [5]. They are composed of stacked, 33
amino acid repeats, each forming a b-turn that is followed by two
antiparallel a-helices and a loop reaching the b-turn of the next
repeat [6]. These repeats are flanked by constant capping regions,
forming one contiguous polypeptide chain. Target protein binding
involves contact through the tips of the b-hairpins and the surface
of the helical bundle facing the concave ankyrin groove [7]. A
library of DARPins was created by varying the number of repeats
and randomizing the seven non-structural residues within the
repeats [4]. We have previously characterized a panel of CD4-
specific DARPins, which efficiently inhibit infection by a broad
range of HIV strains and provided preliminary evidence that
human CD4-specific DARPins bound macaque CD4 and
inhibited SIV replication in vitro, without affecting the CD4
+
memory T cell function [8].
Determining the fate of the DARPins in a relevant animal
model is critical for the advancement of this promising technology
for future topical clinical applications against HIV. Here, for the
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12455first time, we describe the fate of the DARPins in vivo in rhesus
macaques, using CD4-specific DARPins as a tool to provide proof
of concept for their in vivo potential in the development of strategies
against HIV.
Materials and Methods
Production and purification of DARPins
Expression and purification of the DARPins 57.2 and E3_5
were done as described in [8] with minor modifications to remove
endotoxins. After bacterial lysis and binding of the DARPins to the
Ni-NTA Sepharose (Qiagen, Valencia, CA) the column was
initially washed with 30 column volumes (CV) PBS, 350 mM
NaCl, 35 mM Imidazole, pH 7.4 (Wash buffer), followed by 10
CV wash buffer supplemented with 0.1% v/v Triton-X-114
(Sigma, St.Louis, MO). Subsequently the column was re-
equilibrated with wash buffer, washed with 10 CV 50 mM Tris-
HCl, 60% (v/v) isopropanol, pH 7.5 and re-equilibrated with
wash buffer. The bound protein was eluted with wash buffer with
500 mM Imidazole and protein containing fractions were pooled
and dialyzed against PBS at 4uC overnight. To lower the
endotoxin content further the DARPins were rebound to Ni-
NTA and the entire process was repeated. After the 2
nd
purification the proteins were dialyzed as before. The remaining
level of endotoxins in the protein preparations was quantified
using the Endochrome K kit (Charles Rivers Laboratories
International, Inc, L’Arbresle, France). The endotoxin concentra-
tion was 24 and 2 EU/mg protein for 57.2 and E3_5, respectively.
Animals and treatments
Adult (5–9 years old) female Chinese rhesus macaques (Macaca
mulatta) housed at the Tulane National Primate Research Center
(TNPRC; Covington, USA) were either uninfected or chronically
infected (duration of infection <1 year) with SHIV-RT via the
vaginal route (CD4 counts: 131 - 1233, plasma viremia range:
undetectable - 540000, see Table 1). Animals were injected with
30 or 300mg/kg of DARPins 57.2 and E3_5 intravenously. Blood
samples (7.5 ml) and peripheral (axillary and inguinal) lymph node
biopsies were collected at indicated time points after the DARPin
injection. Animals were monitored continuously by veterinarians
and animal care staff to ensure their welfare. The TNPRC
Division of Veterinary Medicine has established procedures to
minimize pain and distress. Animals were anesthetized with either
ketamine (10 mg/kg) or tiletimine/zolazepam (8 mg/kg) for all
procedures and given buprenorphine (0.01 mg/kg) for post-
procedure analgesia. Protocols were reviewed and approved by
the Institutional Animal Care and Use Committee of TNRPC
(OLAW Assurance #A4499-01). Tulane National Primate
Research Center is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC
#000594). Animal care and research procedures were in
compliance with the regulations detailed under the Animal
Welfare Act [9] and in the Guide for the Care and Use of
Laboratory Animals [10].
Isolation of macaque plasma and primary cells
Plasma was isolated by centrifugation of the whole blood twice
at 2000 rpm for 10 minutes at 4uC and collecting the top layer
each time [11]. Plasma virus loads were then determined by the
quantitative RT-PCR assay for SIV gag RNA [12]. Blood was
diluted with an equal volume of cold PBS and PBMCs were
isolated with density gradient centrifugation using Ficoll-Hypaque
(GE Healthcare, Uppsala, Sweden). Lymph node cells were
obtained by mechanical disruption and passage through 70 mm
nylon cell strainers (BD Falcon, Franklin Lakes, NJ) as described
previously [13].
In vitro DARPin binding
For the in vitro binding experiments, 4610
5 cells were incubated
in V-bottom 96-well plates (Cellstar, Carrollton, TX) with 200nM
of DARPin for 20 minutes in 50 ml of FACS wash buffer (FWB)
(PBS/ 1% human serum (Sigma)/ 1mM EDTA (Sigma)).
Unbound DARPins were washed away by adding 150 mlo f
FWB, centrifuging at 2350 rpm for 2 min. This was repeated 3
times before staining.
Flow cytometry
In vitro or in vivo binding of DARPins was measured on PBMCs,
lymph node cells, and whole blood. 10
6 PBMCs and lymph node
cells were plated in V-bottom 96-well plates and 100ml of whole
Table 1. SHIV-RT infected animals that were used for the in vivo DARPin applications.
DARPin treatment Animal ID* Baseline CD4 count (cells/ml) Baseline plasma RNA viral load (copies/ml)
300mg/kg 57.2 HM17 734 9,500
HM30 781 9,000
HM37 131 170,000
HM24 170 130,000
HM28 972 ,30
HM36 617 540,000
30mg/kg 57.2 HM20 1102 40
HM26 190 19,000
GT61 800 120
300mg/kg E3_5 HM36 802 240,000
HM27 293 120,000
HM28 1233 30
HM30 982 18,000
*3 animals are listed twice, because they were treated with the two DARPins on separate occasions.
doi:10.1371/journal.pone.0012455.t001
CD4-Specific DARPin In Vivo
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12455blood placed in a FACS tube (BD Falcon). Bound His-tagged
DARPins were detected by staining for 30 minutes at 4uC (isolated
cells) or room temperature (whole blood) with 1/100 dilution of
anti-Penta-His Alexa Fluor 647 conjugate (Qiagen) and combined
with staining for several surface markers where indicated; 1/50
dilution of FITC-anti-CD3 (clone SK7), FITC-anti-CD14 (clone
M5E2), FITC-anti-CD20 (clone L27), PE- and PerCP-anti-CD4
(clone L200), PE-anti-CD123 (clone 7G3), PerCP- and APC-anti-
HLA-DR (clone L243) antibodies (all from BD Biosciences, CA).
‘‘Lineage’’ staining was performed with anti-CD3, -CD14 and
-CD20 antibodies. The combinations used for cell staining
were anti-CD3/anti-CD4/anti-His, anti-CD14/anti-CD4/anti-
His, anti-CD20/anti-CD4/anti-His, anti-Lineage/anti-CD123/
anti-DR/anti-His and anti-Lineage/anti-CD123/anti-CD4/anti-
HLA-DR. For whole blood, red blood cells were lysed with 2 ml of
the FACS lysing solution (BD Biosciences) for 10 minutes. All
samples were washed 3 times with FWB, fixed in 100 mlo fB D
Cytofix and acquired on a FACSCalibur (BD Biosciences), and
analyzed using FlowJo software (Tree Star, CA). Appropriate
irrelevant specificity isotype Ig negative controls were included in
all experiments and typically gave MFIs of ,1 log.
In vitro retention of CD4 DARPins
10
6 PBMCs from macaques that had been injected with
DARPins were cultured in 48-well plates (BD Falcon) in 250 mlo f
R10 medium (RPMI containing 10% fetal calf serum, 2 mM L-
glutamine, 10mM HEPES, 50mM b-mercaptoethanol and peni-
cillin/strepomycin). Cells were harvested at various timepoints and
labeled with anti-CD4-PE and anti-Penta-His Alexa Fluor 647
antibodies.
In vitro infection assays
3610
7 macaque PBMCs were cultured in 15 ml of R10
medium in the presence of 5mg/ml PHA (Sigma). After 3 days,
cells were resuspended at the same density in R10 medium
containing 50 U/ml IL-2 (Roche, Basel, Switzerland) and plated
in a 96-well flat bottom plate at a concentration of 2610
5 cells/
well. Cells were preincubated for 1 hour at 37uC with titrated
doses of DARPins, before adding 200 TCID50/well of SIV
mac239 or SHIV-RT (SIVmac239 with the HIV RT [11,24]).
Cultures were kept at 37uC, fed with 50 U/ml of IL-2 every 2 days
and supernatants collected 7 days after infection. P27 concentra-
tions in the supernatants were quantified using the RETRO-TEK
SIV p27 Antigen ELISA kit (ZeptoMetrix, Buffalo, NY), according
to the manufacturer’s instructions.
Detection of free DARPin in the plasma
Opaque 96-well plates were coated with 10nM anti-human IgG
(I5260, Sigma) in TBS and blocked with TBST (TBS with 0.05%
tween)/1% BSA. After washing three times with TBST, 10nM
PRO 542 (CD4IgG2) (Progenics Pharmaceuticals, Tarrytown,
NY) was added in the blocking buffer. Following another series of
washes, samples diluted in TBST were added to the wells, washed
out and labeled with anti-His-tag antibody (A5588, Sigma). After a
series of washes with TBST and the Tropix buffer (Applied
Biosystems, Foster City, CA), CDP star (MS1000RX, Applied
Biosystems) was added and the plate read on the SpectraMax
Gemini EM luminometer (Molecular Devices, Sunnyvale, CA).
Volumes of 100ml and incubation times of 1 hour were used for
each step. All samples were run in duplicates. Pharmacokinetic
analysis was performed using the NONMEM software (ICON
Development Solution, Ellicott City, MD). Statistical analysis was
performed using GraphPad Prism software (GraphPad Software,
San Diego, CA).
Results
Identification of potent macaque CD4-binding DARPins
We previously demonstrated the ability of human CD4-specific
DARPins to cross-react with macaque CD4 [8]. This opened up a
possibility of studying these inhibitors in a relevant animal model
to establish whether DARPins had the potential be used in vivo.T o
move forward with the most potent DARPins, the second-series
DARPins 55.2 and 57.2, which show strong binding to human
CD4 and inhibition of HIV infection in vitro [8], were examined
for macaque reactivity. Both of them, but not the control DARPin
E3_5, bound CD4+ T cells isolated from macaque blood
(Figure 1A). More DARPin 57.2 bound to macaque CD4+ T
cells compared to DARPin 55.2. We then compared the ability of
DARPins 55.2 and 57.2 to block SIV infection of primary
macaque PBMCs. Both DARPins blocked SIV mac239 infection
of cells derived from all three naı ¨ve animals that were tested.
DARPin 57.2 had a mean IC90 of 0.8nM which is ,10 times less
than was required from either DARPin 55.2 (Figure 1B) or the
previously studied DARPin 25.2 [8]. Therefore, DARPin 57.2 was
selected for more extensive analyses and for the evaluation in vivo
in macaques.
To further characterize the cells that were bound by the CD4-
specific DARPin 57.2, we co-stained the DARPin-exposed
PBMCs for various cell markers (Figure 1C). As expected, CD4
+
T cells were stained with the highest intensity. CD123
+
plasmacytoid DCs (Lineage
2HLA-DR
+CD123
+) stained stronger
than the myeloid DC-containing fraction (Lineage
2HLA-
DR
+CD123
2) and monocytes (CD14
+), which were only weakly
positive. B cells (CD20
+) and CD3
+CD4
2 T cells were not stained
above background levels. DARPin 57.2 partially blocks binding by
the anti-CD4 MAb L200 used herein (Figure S1). Therefore,
relative cell surface CD4 expression of different macaque
leukocyte cell subsets was done in parallel on the cells from the
same animal. There was a perfect positive linear association
between the cell surface CD4 expression by the different cell types
and staining with DARPin 57.2 (Spearman’s r=1, p=0.003)
(Figure 1D and Table 2). As expected, the amount of DARPin
57.2 binding to primary CD4
+ cells was dependent on the input
dose (Figure 1E). Binding started to plateau around 100nM and
half-maximal binding was achieved at <3nM of DARPin 57.2.
Binding fell below detection limits at concentrations below 0.3nM.
DARPin 57.2 also bound CD4
+ T cells in macaque lymph node
cell suspensions, similar to the amount bound to blood cells
(Figure 1F vs 1A and 1C). Although there was more non-specific
staining with the control DARPin E3_5 in lymph node cell
suspensions, due to background from the secondary anti-His
antibody (data not shown), the DARPin 57.2 staining of the CD4
+
T cells was significantly above background of the control DARPin
E3_5-treated cells (p=0.01, Mann-Whitney test). Just as in blood,
staining of CD4
2 T cells by DARPin 57.2 was not higher than the
staining with a control DARPin (Figure 1F).
DARPin 57.2 is rapidly cleared from circulation after
intravenous injection
To investigate the potential of the DARPin application in vivo,
DARPins 57.2 or E3_5 were administered via intravenous
injection to clinically stable, SHIV-RT infected macaques
(available from other completed studies). Overall, 6 animals
received a high dose (300mg of DARPin 57.2 per kg of weight) and
3 animals received a low dose (30mg of DARPin 57.2 per kg of
weight) (Table 1). The 300mg/kg injection was intended to achieve
the initial plasma concentration of <230nM, which is similar to
concentrations used in our in vitro experiments. As controls, 4
CD4-Specific DARPin In Vivo
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DARPin E3_5. Blood samples were taken immediately before the
injection, as well as 30 minutes, 2 hours, 6 hours, 24 hours,
48 hours and 7 days after the injection.
Unbound CD4-specific DARPin 57.2 was detectable in the
plasma of macaques within 30 minutes after injection (Figure 2).
By the 2-hour mark, only 2–4% of the injected DARPin 57.2
remained free in the plasma. By the 6-hour time point, the plasma
levels of DARPin 57.2 were already below the level of detection of
the assay (<50 pM) for the low dose group of macaques. Free
DARPin was still detectable in the plasma of animals that received
the high dose of DARPin 57.2 at 6 hours post-injection, but fell
below the detection limit by 24 hours post-injection. The log scale
DARPin 57.2 concentration vs. time plot did not yield a straight
Figure 1. CD4-specific DARPin 57.2 binds to macaque CD4
+ cells. A. PBMCs were incubated with 200nM of DARPins 57.2, 55.2 or E3_5 for
30 minutes before being labeled with antibodies for CD3, CD4 and His-tag. Mean fluorescent intensities (MFIs) of the anti-His staining on the
indicated subsets identified within a total leukocyte gate from 4 independent experiments are shown (mean6SEM). B. PBMCs were pretreated with
the indicated concentration of DARPins 57.2, 55.2 or E3_5 and then exposed to SIVmac239. 7 days later the amount of p27 in the culture supernatant
was quantified by ELISA. The values shown are the means (6SEM) from 3 independent experiments and are normalized to the amount of p27
produced in the absence of inhibitors (i.e. 100% replication). C. PBMCs were incubated with 200nM of DARPins 57.2 or E3_5 for 30 minutes before
being labeled with antibodies for CD3, CD4, CD14, CD20, CD123, HLA-DR and His-tag, as indicated. MFIs (mean6SEM) of the anti-His staining on the
indicated subsets identified within a total leukocyte gate from 5 independent experiments are shown. The DC-containing fractions were identified
within the Lineage
2HLA-DR
+CD123
2 (CD1232, myeloid DC-containing fraction) or the Lineage
2HLA-DR
+CD123
+ (CD123+, plasmacytoid DCs). D. The
different cell types defined in panel C were stained with anti-CD4 (in the absence of DARPin 57.2) or anti-His (in the presence of DARPin 57.2) in
parallel and the CD4 MFIs determined (Table 2). Each point on the graph represents a distinct cell type. Linear regression and correlation were
performed using the GraphPad Prism software. An average of MFIs of the anti-His (DARPin) and anti-CD4 staining for each indicated cell type from 3
independent experiments is shown. E. PBMCs were incubated with various concentrations of DARPin 57.2, labeled with the anti-penta His antibody
and analyzed by flow cytometry. MFIs (mean6SEM) from 2 independent experiments are shown. Curve fitting was done using the GraphPad Prism
software. F. Lymph node cells were incubated with 200nM of the DARPin 57.2 or E3_5 and stained for His and CD4. MFIs (mean6SEM) of the anti-His
staining of the gated CD4+ cell population from 5 independent experiments are shown.
doi:10.1371/journal.pone.0012455.g001
Table 2. Cell-surface staining for DARPin 57.2 binding (His)
and CD4 by various types of macaque leukocytes.
Cell type CD4 MFI His MFI
CD3
+CD4
+ 381630 7936247
CD3
+CD4
2 6611 0 61
CD14
+ 30638 2 619
CD20
+ 13643 6 69
Lineage
2HLA-DR
+CD123
+ 192656 311693
Lineage
2HLA-DR
+CD123
2 29684 2 63
Means6SEM from 3 independent experiments are shown.
doi:10.1371/journal.pone.0012455.t002
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(Figure 2). The clearance rate (CL), volume of distribution (Vd)
and a-half-life (T1/2) of DARPin 57.2 all increased with the
increase in input DARPin dose (Table 3).
Since we used macaques that were previously infected with
SHIV-RT, we looked at the plasma viral loads at various time
points after the injection with the high dose of DARPin 57.2 to
check if the one-time DARPin treatment had an effect on the
infection. 3 of 6 animals had high pre-treatment virus loads (.10
5;
range 130,000–540,000 copies/ml), 2 of 6 animals had interme-
diate virus loads (,10
4; range 9,000–9,500 copies/ml), and 1
animal had only 200 copies/ml (Table 1). As predicted, a single
dose of DARPin 57.2 did not alter the plasma viral load compared
to the DARPin E3_5 controls (Figure 3). Decreases of up to 1 log
in plasma SIV RNA were observed in some animals but this was
not sustained and seen in both groups of animals. To be sure that
the lack of effect on SHIV-RT in vivo was not due to an inability of
DARPin 57.2 to block SHIV-RT infection, the inhibition of
SHIV-RT infection of activated PBMCs by DARPin 57.2 was
measured. DARPin 57.2 also blocked the infection of macaque
PBMCs with SHIV-RT (IC90,10nM, Figure S2). There were also
no sustained changes in numbers of circulating CD4
+ T cells (data
not shown).
DARPin 57.2 rapidly binds cell-surface CD4 in vivo
To investigate whether the circulating CD4-specific DARPin
would bind CD4
+ cells in vivo we sampled blood and lymph nodes
at various time after injection. Initially, PBMCs were co-stained
for CD4 and penta-His. Virtually all cells in the CD4
+ gate were
DARPin-positive and expressed similar levels of DARPin to that
bound in vitro 30 minutes after DARPin 57.2 injection (Figure 4A).
The level of staining was dependent on the input dose of DARPin
57.2, as seen in our in vitro binding studies (Figure 1E). The staining
was weaker by 6 hours post-injection (but all CD4
+ cells were
DARPin positive) and was down to background levels by 24 hours
for the low dose group. Weak staining was still detected at the
24 hour mark after the injection with 300mg/kg of DARPin 57.2
(Figures 4A and S3). To ensure that the DARPin binding detected
in the PBMCs was not simply due to the cell-free DARPins in the
plasma binding to cells during the overnight shipment of the blood
to the laboratory, we carried out the His staining on whole blood
samples immediately upon collection from the animals. Similar to
the PBMC results, His-positive cells were detected in whole blood
30 minutes after injection with DARPin 57.2, with the level of
staining decreasing by 6 hours and being undetectable after
24 hours (Figure 4B and S3). Therefore, there was little
contribution from cell-free DARPins in the plasma DARPin
binding to cells during the shipment.
In order to determine if the DARPins circulated from the blood
to the lymph nodes, superficial lymph nodes were first sampled 24,
48 and 168 hours after the injection of DARPin 57.2 vs the control
DARPin E3_5. Lymph node cells were stained for CD4 and
penta-His. After 24 hours, binding by DARPin 57.2, but not by
DARPin E3_5, was detected on CD4
+ cells (Figure 4C). As seen in
the peripheral blood, no DARPin binding was seen at later time
points. The level of His staining (DARPin binding) was
comparable to the levels seen at the 24 hour time point in the
blood (compare the MFIs in panel 4A and 4C for the 300mg/kg
dose). Therefore, we examined earlier time points to ascertain
whether higher levels were also present in the lymph nodes earlier
(as in the blood). To do this, a separate set of animals were injected
with 300mg/kg DARPin 57.2 and lymph nodes and blood
collected 0.5, 6, and 24 hours later. Analysis of these acute time
points revealed that CD4
+ cells in the lymph nodes were already
bound by DARPin 57.2 30 minutes after the injection (Figure 4D).
The levels of DARPin binding to the cells was lower in the lymph
nodes than in the peripheral blood after 30 minutes, but was at
similar levels after 6 and 24 hours (Figure 4D). As in blood, the
entire CD4
+ T cell population in the lymph nodes bound the
DARPins.
To better understand the mechanism by which the levels of cell
bound DARPin 57.2 were decreasing with time, we isolated
macaque PBMCs 30 minutes after injection with DARPin 57.2
and cultured them in vitro. Levels of cell-bound DARPin 57.2
decreased with time during the in vitro culture (Figure 5A). The
cells retained DARPin 57.2 longer in culture than they did in the
peripheral blood: some DARPin-bound cells were still present
after 5 days in culture, while none were detected in the peripheral
blood by 48 hours (Figures 4B and 5A). The decrease in DARPin
binding was not due to a change in CD4
+ cell numbers (Figure 5B).
There was also no apparent decrease in cell-surface levels of CD4,
although we could not accurately quantify levels of cell surface
Figure 2. The rate of clearance of DARPin 57.2 from plasma is
rapid and dose-dependent. Free DARPin 57.2 concentration in
macaque plasma sampled at various times post injection was measured
using a sandwich ELISA. Concentrations (mean6SEM) for both DARPin
57.2 doses are shown at each indicated time point. 6 animals received
300mg/kg and 3 animals received 30mg/kg of DARPin 57.2.
doi:10.1371/journal.pone.0012455.g002
Table 3. Pharmacokinetic parameter estimates for DARPin 57.2.
DARPin 57.2 dose, mg/kg b-t1/2,h r a-t1/2,h r V d, L/kg CL, L/hr AUC, nmoles/hr
300 1.30 (0.15) 0.48 (0.98) 0.16 (0.05) 0.12 (0.04) 198.0
30 1.34 (0.01) 0.05 (0) 0.07 (0) 0.03 (0) 8.3
NONMEM software was used to perform the analysis of the data with the IV 2-compartment model. Means (SD) for the following parameters are shown: t1/2, half-life
(given for the two phases, as indicated); Vd, volume of distribution, CL, clearance rate; AUC, area under the concentration-time curve. AUC was calculated using the
GraphPad Prism software.
doi:10.1371/journal.pone.0012455.t003
CD4-Specific DARPin In Vivo
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CD4 MAbs (Figures 5C and S1).
More extensive analyses were performed on the blood cells to
establish which CD4
+ cells bound the DARPins in vivo. Multicolor
staining was performed on blood cells collected at different times
post DARPin injection. In vivo, the pattern of DARPin 57.2
binding to cells resembled that seen in vitro (Figures 1B and 6). All
CD4
+ (but not CD4
2) cells bound DARPin 57.2 proportional to
the level of surface CD4 expressed. On all cell types, the greatest
binding was seen at the earliest time point (30 minutes) after
injection, the amounts decreasing similarly thereafter irrespective
of cell type. DARPin 57.2 binding only persisted on CD4
+ T cells
after 24 hours, albeit at low levels. Therefore, DARPin 57.2
functions normally in vivo, binding to target CD4
+ cells in a
specific, dose-dependent manner.
Discussion
Small proteins such as DARPins may prove to be a useful
alternative to antibodies, which have disadvantages such as high
cost, low stability and poor tissue penetration. Experiments done in
vitro demonstrated that DARPins can bind their targets with high
affinity and high selectivity [8,14–16]. A proof of concept study
was needed to investigate whether these small proteins demon-
Figure 3. A single injection with a CD4-specific DARPin 57.2 does not lead to a change in plasma RNA viral load in rhesus macaques
infected with SHIV-RT. Plasma samples were taken from the macaques at indicated timepoints after an injection with 300mg/kg of DARPin 57.2
and E3_5. SIV RNA copy numbers were determined by qRT-PCR. Each line represents an individual animal.
doi:10.1371/journal.pone.0012455.g003
Figure 4. Injection of macaques with DARPin 57.2 results in transient binding to CD4
+ cells. A. Blood samples were taken from macaques
at indicated timepoints after an injection with DARPin. PBMCs were isolated, labeled with antibodies to CD4 and to penta-His and analyzed by flow
cytometry. The MFI (mean6SEM) of His staining on CD4
+ cells within a total leukocyte gate is shown for animals injected with 300mg/kg DARPin 57.2
(n=6), 30mg/kg DARPin 57.2 (n=3) or DARPin E3_5 (n=5). Data from both doses of DARPin E3_5 was combined for simplicity. B. Whole blood
samples taken after DARPin injection were immediately labeled with the anti-His antibody and analyzed by flow cytometry. The MFIs (mean6SEM) of
His
+ cells are shown for animals injected with 300mg/kg DARPin 57.2 (n=6), 30mg/kg DARPin 57.2 (n=3) or DARPin E3_5 (n=5). Lymph nodes (C and
D) and blood (D) were taken from macaques at indicated timepoints after an injection with DARPin. Isolated cells were labeled with antibodies to
penta-His and CD4 and analyzed by flow cytometry. MFIs (mean6SEM) of gated CD4
+ cells are shown for animals injected with 300mg/kg DARPin 57.2
(C,n=7 ;D n=4) or DARPin E3_5 (C, n=6).
doi:10.1371/journal.pone.0012455.g004
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identification of human CD4-specific DARPins that specifically
bound to human and macaque CD4 and inhibited HIV and SIV
infection in vitro [8]. In this study, we characterized a more potent
second series CD4-specific DARPin 57.2 for macaque reactivity
and investigated its activity after a single intravenous injection into
rhesus macaques.
DARPin 57.2 was chosen due to its higher levels of binding and
more effective inhibition of SIV infection in vitro. Here we
demonstrate that it rapidly binds CD4
+ cells in vivo. DARPin-
bound cells were detected 30 minutes after the intravenous
injection not only in the peripheral blood, but also in the
lymphoid tissue. DARPin could be reaching the tissue in its free
form and binding resident cells there and/or we could be detecting
cells that have bound DARPin in the periphery and migrated to
the lymph node. If only the latter scenario were true, one would
expect to find at least some tissue-resident CD4
+ cells that are
DARPin-negative, while we find that all of the CD4
+ cells in the
lymph node are bound by the DARPin 57.2. Therefore, it is likely
that free DARPins can rapidly reach the lymphoid tissue and bind
resident cells there.
We found that the clearance of DARPin 57.2 from the plasma
was rapid, but the rate increased with the increase in dose,
suggesting that DARPin elimination is a saturable process.
Similarly rapid plasma clearance rate was also observed when a
HER2-specific DARPin of a comparable size was used in mice
[17]. The dynamics of the loss of CD4
+ cell-bound DARPins were
slower, but generally similar to that of the free DARPin in the
plasma. The binding of DARPin 57.2 to primary cells was also
short-lived when cells were cultured in vitro. Additional studies are
needed to determine what happens to the CD4-specific and other
DARPins after they bind their targets.
The binding levels of the DARPin 57.2 were determined by the
levels of cell surface CD4 expression. Hence, binding of the
DARPin 57.2 to CD4 on various cell types was likely not affected
by possible cell type-dependent differences in CD4 conformations
or associations of CD4 with other cell surface molecules. The vast
majority of DARPin 57.2-binding cells in macaques were CD4
+ T
cells, which also had the highest levels of CD4. Unlike human
monocytes, macaque monocytes have relatively low levels of CD4
expression, which resulted in low levels of binding by DARPin
57.2. In contrast, macaque CD123
+ pDCs had higher levels of
CD4 expression than monocytes or myeloid DCs [18] and
consequently high levels of DARPin 57.2 binding. The functional
importance of CD4 expression by these cell types and the precise
role these cell types play during retroviral infection is not yet fully
understood.
Monoclonal antibodies to CD4 can potently inhibit infection of
T cells by primary HIV-1 isolates in vitro, including strains that are
resistant to other types of HIV inhibitors [19]. One of the CD4-
specific MAbs, Ibalizumab, substantially reduces HIV-1 RNA
levels in infected people and is currently in advanced clinical trials
[20]. However, single infusions with Ibalizumab did not lead to
decreases in plasma viral loads at doses below 3mg/kg [21]. In our
study the highest dose of DARPin 57.2 was 300mg/kg, which is
slightly lower than 3mg/kg of antibody in terms of molarity.
Hence, given the faster plasma clearance rate of the DARPins, a
reduction in the plasma viral load was not a likely outcome. Since
Figure 5. Bound DARPin 57.2 is not retained long term on macaque cells. PBMCs were collected 30 minutes after DARPin injection and
cultured in vitro for 7 days. Cells were harvested at the indicated timepoints, labeled for His and CD4 and analyzed by flow cytometry. (A) The MFIs
(mean6SEM) of His staining on CD4
+ cells are shown for animals injected with 300mg/kg DARPin 57.2 (n=4) or DARPin E3_5 (n=3). Baseline samples
were taking from the same animals immediately before the injections (pre). The percentage of CD4
+ cells (B) and the MFIs of CD4 expression (C) for
the samples described in panel A were also measured over time.
doi:10.1371/journal.pone.0012455.g005
Figure 6. DARPin 57.2 binding to macaque leukocyte cell types in vivo. PBMCs were prepared from blood samples taken from macaques at
30 minutes, 6 hours or 24 hours after an injection with 300mg/kg of DARPin 57.2 (n=6) or DARPin E3_5 (n=4). Cells were stained the various
antibody combinations (same as in Figure 1C) to define the indicated subsets. An average of MFIs (mean6SEM) of the anti-His staining for each
indicated cell type is shown.
doi:10.1371/journal.pone.0012455.g006
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RT, we checked their plasma RNA levels and confirmed our
predictions that a single injection of DARPin 57.2 had no effect on
the SHIV-RT plasma RNA levels. CD4-specific DARPin 57.2 did
not cause a rapid flux of CD4
+ T cells from the lymphoid tissue
into peripheral blood, which was seen in Ibalizumab-treated
people and macaques [21,22]. Possibly this is caused by the
cellular reaction to rapid internalization of CD4, which is induced
by antibody binding but not by DARPin binding [8,23].
Antiviral therapies targeted at CD4 can potentially have an
undesired immunomodulatory effect, by either signaling through
CD4 or blocking the interactions with MHC class II. CD4-specific
DARPins were shown to have no effect on T cell proliferation, DC
activation or overall cell viability in vitro [8]. Although unexpected,
we were not yet able to assess DARPin 57.2 effect on
immunological functions in vivo due to the limitations of the
animal samples, but it will be looked at closer in the future studies.
Overall, our data demonstrates that DARPins can rapidly,
potently and selectively bind their targets in vivo, even in the tissues,
opening the doors for future development for novel treatment of
HIV and other conditions. The high stability and low production
costs could also make antiviral DARPins a promising candidate for
the HIV prevention treatment, sorely needed due to the lack of
effective vaccines. Topical vaginal microbicides can prevent
mucosal transmission of the virus [11,24–26]. Blocking the
gp120 interaction with CD4 by a small molecule BMS-378806
protected most macaques from vaginal SHIV challenge, verifying
that the CD4-envelope interaction is a possible target for a
microbicide [25]. There are few CD4+ cells in the vaginal mucosal
tissue, which makes it difficult to reliably quantify the kinetics and
the effectiveness of CD4-specific DARPin binding after it is
applied topically. Therefore we chose the systemic intravenous
administration of the drug to provide the proof of concept that it
could be used in vivo. Future studies in naı ¨ve animals will determine
the potential of topically applied DARPins in the prevention of
mucosal HIV infection.
Supporting Information
Figure S1 PBMCs were incubated with 200nM of DARPin 57.2
or in medium alone for 30 minutes before being labeled with
L200, an antibody to CD4. MFIs of the L200 staining from 4
independent experiments are shown.
Found at: doi:10.1371/journal.pone.0012455.s001 (0.45 MB
TIF)
Figure S2 PBMCs were pretreated with the indicated concen-
tration of DARPin 57.2 and then exposed to SHIV-RT. 7 days
later the amount of p27 in the culture supernatant was quantified
by ELISA. The values shown are the means (6 SEM) from 4
independent experiments and are normalized to the amount of
p27 produced in the absence of inhibitors (i.e., 100% replication).
Found at: doi:10.1371/journal.pone.0012455.s002 (0.47 MB TIF)
Figure S3 A. PBMCs were labeled with antibodies to CD4 and
to penta-His and analyzed by flow cytometry. B. Whole blood
samples taken after DARPin injection were immediately labeled
with an antibody to penta-His and analyzed by flow cytometry.
Blood samples were taken from macaques at 0, 0.5, 6, 24 and
48 hour timepoints after an injection with 300 mg/kg DARPin
57.2 (A and B, top rows) or 300 mg/kg DARPin E3_5 (A and B,
bottom rows), as indicated. All cells within a total leukocyte gate
for one representative animal are shown. This macaque, HM28,
has received the two DARPins on separate occasions (Table 1).
Found at: doi:10.1371/journal.pone.0012455.s003 (0.80 MB TIF)
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